Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management
- PMID: 39096927
- DOI: 10.1016/S0140-6736(24)00975-9
Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management
Conflict of interest statement
ER reports grants from Gilead (institutional); travel, accommodations, and expenses fees from Pfizer, Roche, Mundipharma, Eli Lilly, Gilead, and Novartis; and honoraria for lectures or presentations from Eli Lilly, Seagen, and Novartis none of which are related to the treatment of CUP. FAG reports speakers bureau and consultancy fees as a medical adviser from Hologic–Biotheranostics that has a molecular classifier assay for CUP. NP declares no competing interests.
Comment on
-
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.Lancet. 2024 Aug 10;404(10452):527-539. doi: 10.1016/S0140-6736(24)00814-6. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096924 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
